Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Kevin W. Olden, William D. Chey, Reshma Shringarpure, Jean Paul Nicandro, Emil Chuang & David L. Earnest. (2019) Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome. Current Medical Research and Opinion 35:3, pages 461-472.
Read now
Read now
Konstantinos C Fragkos. (2017) Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea. Clinical and Experimental Gastroenterology 10, pages 229-240.
Read now
Read now
Articles from other publishers (11)
Michael Camilleri & Saam Dilmaghani. (2023) Update on treatment of abdominal pain in irritable bowel syndrome: A narrative review. Pharmacology & Therapeutics 245, pages 108400.
Crossref
Crossref
Christopher J Black, Nicholas E Burr, Michael Camilleri, David L Earnest, Eamonn MM Quigley, Paul Moayyedi, Lesley A Houghton & Alexander C Ford. (2020) Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis. Gut 69:1, pages 74-82.
Crossref
Crossref
Christopher N Andrews & Marc Bradette. (2019) Diarrhea-Predominant Irritable Bowel Syndrome: Medical Management Update. Journal of the Canadian Association of Gastroenterology.
Crossref
Crossref
Yi Zheng, Samuel Obeng, Huiqun Wang, David L. Stevens, Essie Komla, Dana E. Selley, William L. Dewey, Hamid I. Akbarali & Yan Zhang. (2018)
Methylation Products of 6β-
N
-Heterocyclic Substituted Naltrexamine Derivatives as Potential Peripheral Opioid Receptor Modulators
. ACS Chemical Neuroscience 9:12, pages 3028-3037.
Crossref
Crossref
Brian E. Lacy, Jean Paul Nicandro, Emil Chuang & David L. Earnest. (2018) Alosetron use in clinical practice: significant improvement in irritable bowel syndrome symptoms evaluated using the US Food and Drug Administration composite endpoint. Therapeutic Advances in Gastroenterology 11, pages 175628481877167.
Crossref
Crossref
Thomas C. Marbury, Jolene Kay Berg, Leonard S. Dove & Paul S. Covington. (2017) Effect of Hepatic Impairment on Eluxadoline Pharmacokinetics. The Journal of Clinical Pharmacology 57:11, pages 1454-1459.
Crossref
Crossref
Sherry Levio & Brooks D. Cash. (2017) The place of eluxadoline in the management of irritable bowel syndrome with diarrhea. Therapeutic Advances in Gastroenterology 10:9, pages 715-725.
Crossref
Crossref
J Tack, K Schumacher, G Tonini, S Scartoni, A Capriati & C A Maggi. (2017) The neurokinin-2 receptor antagonist ibodutant improves overall symptoms, abdominal pain and stool pattern in female patients in a phase II study of diarrhoea-predominant IBS. Gut 66:8, pages 1403-1413.
Crossref
Crossref
Longtu Chen, Sheikh J. Ilham & Bin Feng. (2017) Pharmacological Approach for Managing Pain in Irritable Bowel Syndrome: A Review Article. Anesthesiology and Pain Medicine 7:2.
Crossref
Crossref
W. E. Whitehead, K. Duffy, J. Sharpe, T. Nabata & M. Bruce. (2017) Randomised clinical trial: exploratory phase 2 study of ONO-2952 in diarrhoea-predominant irritable bowel syndrome. Alimentary Pharmacology & Therapeutics 45:1, pages 14-26.
Crossref
Crossref
Giuseppe Esposito, Nicola Nobile, Stefano Gigli, Luisa Seguella, Marcella Pesce, Alessandra d’Alessandro, Eugenia Bruzzese, Elena Capoccia, Luca Steardo, Rosario Cuomo & Giovanni Sarnelli. (2016) Rifaximin Improves Clostridium difficile Toxin A-Induced Toxicity in Caco-2 Cells by the PXR-Dependent TLR4/MyD88/NF-κB Pathway. Frontiers in Pharmacology 7.
Crossref
Crossref